MedTrace Logo

Efficacy and Safety/Tolerability of Ragweed MATA MPL

NCT00423787 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 993

Last updated 2010-06-17

No results posted yet for this study

Summary

Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis with or without mild to moderate asthma bronchiale. The purpose of this study is to compare the efficacy of Ragweed MATAMPL versus placebo in ragweed-allergic subjects following 4 subcutaneous injections of study medication administered before the start of the 2007 ragweed pollen season

Conditions

  • Type I Hypersensitivity

Interventions

BIOLOGICAL

Ragweed MATA MPL

4 injections of increasing dose strength: 1. 300 SU/0.5 ml 2. 700 SU/0.5 ml 3. 2000 SU/0.5 ml 4. 6000 SU/0.5 ml

Sponsors & Collaborators

  • Allergy Therapeutics

    lead INDUSTRY

Principal Investigators

  • Karl Jürgen Fischer von Weikersthal-Drachenberg, MD · Allergy Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-11-30
Completion
2008-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423787 on ClinicalTrials.gov